A new analysis spotlights operational bottlenecks in the logistics of next-generation cell and gene therapies, where delivery windows and product sensitivity can be measured in minutes. The report details why CGT supply chains require specialized handling, visibility into critical parameters, and tightly controlled packaging validation—highlighting how scheduling disruptions can force leukapheresis repeats or manufacturing rebuilds.